Ítem
Solo Metadatos
Intravitreal bevacizumab (Avastin®) for diabetic retinopathy at 24-months: The 2008 Juan Verdaguer-planas lecture
Título de la revista
Autores
Arevalo J.F.
Sanchez J.G.
Lasave A.F.
Wu L.
Maia M.
Bonafonte S.
Brito M.
Alezzandrini A.A.
Restrepo N.
Berrocal M.H.
Fecha
2010
Directores
ISSN de la revista
Título del volumen
Editor
Bentham Science Publishers B.V.
Buscar en:
Métricas alternativas
Resumen
Abstract
Diabetic retinopathy (DR) remains the major threat to sight in the working age population. Diabetic macular edema (DME) is a manifestation of DR that produces loss of central vision. Proliferative diabetic retinopathy (PDR) is a major cause of visual loss in diabetic patients. In PDR, the growth of new vessels is thought to occur as a result of vascular endothelial growth factor (VEGF) release into the vitreous cavity as a response to ischemia. Furthermore, VEGF increases vessel permeability leading to deposition of proteins in the interstitium that facilitate the process of angiogenesis and macular edema. This review demonstrates multiple benefits of intravitreal bevacizumab (IVB) on DR including DME and PDR at 24 months of follow up. The results indicate that IVB injections may have a beneficial effect on macular thickness and visual acuity (VA) in diffuse diabetic macular edema. Therefore, in the future this new therapy could replace or complement focal/grid laser photocoagulation in DME. In PDR, this new option could be an adjuvant agent to pan-retina photocoagulation so that more selective therapy may be applied. In addition, we report a series of patients in which tractional retinal detachment developed or progressed after adjuvant preoperative IVB in severe PDR. © 2010 Bentham Science Publishers Ltd.
Palabras clave
Keywords
Bevacizumab , Angiogenesis inhibitor , Bevacizumab , Monoclonal antibody , Article , Diabetic macular edema , Diabetic retinopathy , Disease severity , Follow up , Human , Laser coagulation , Macular thickness , Priority journal , Proliferative diabetic retinopathy , Retina detachment , Treatment outcome , Visual acuity , Adult , Aged , Animal , Article , Cell proliferation , Diabetic retinopathy , Drug effect , Evaluation , Female , Intravitreal drug administration , Male , Middle aged , Optical coherence tomography , Retina macula edema , Retrospective study , Time , Adult , Aged , Angiogenesis inhibitors , Animals , Antibodies , Cell proliferation , Diabetic retinopathy , Female , Follow-up studies , Humans , Intravitreal injections , Macular edema , Male , Middle aged , Retrospective studies , Time factors , Tomography , Diffuse diabetic macular edema , Intravitreal bevacizumab , Panretinal photocoagulation , Proliferative diabetic retinopathy , Tractional retinal detachment , Vascular endothelial growth factor
